期刊
TRANSPLANTATION
卷 94, 期 8, 页码 784-793出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0b013e318269e64f
关键词
Epstein-Barr virus infection; Immunosuppression; Lymphoproliferative disorder; Transplantation
资金
- Genzyme
- CSL Behring
- Mundipharma
- Amgen
- Roche
- BMS
- Pfizer
- Astellas
- Novartis
- Fresenius
- Medical Research Council [G9818340B] Funding Source: researchfish
Posttransplant lymphoproliferative disorders (PTLDs) are associated with significant morbidity and mortality among solid-organ transplant patients, but approaches to diagnosis and management vary considerably. An international multidisciplinary panel evaluated current understanding of risk factors and classification systems and developed recommendations to aid in PTLD prevention. We considered evidence on PTLD risk factors including Epstein- Barr virus serostatus and immunosuppression and identified knowledge gaps for future research. Recommendations address prophylactic and preemptive strategies to minimize PTLD development, including modulation of immunosuppression and antiviral drug regimens. Finally, new classification criteria were outlined that may help facilitate standardized reporting and improve our understanding of PTLD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据